HTC VIVE Eagle AI 眼鏡支援 ChatGPT、Google Gemini 助手，挑戰 Ray-Ban Meta、小米 AI 眼鏡
由 Meta Ray-Ban AI 眼鏡引起的新一輪穿戴式裝置潮流，長期耕耘在 VR 眼鏡的 HTC 也要來跨界挑戰。今天 HTC 宣佈推出全新 VIVE Eagle AI 眼鏡，以多色半透明鏡框配上蔡司 UV400 太陽眼鏡鏡片的潮流外型，以支援多個 AI 模型和用戶數據不上網為賣點，挑戰 Ray-Ban Meta 和小米 AI 眼鏡。
就與市場上其他 AI 眼鏡競品同樣，HTC VIVE Eagle AI 眼鏡能透過 12MP 超廣角相機拍攝和錄影第一身視角、透過選定的 AI 模型來翻譯眼前文字、語音設定 AI 備忘錄。HTC 主打穩私安全，包括 HTC VIVE Eagle AI 眼鏡的相機在作用時會有 LED 燈號，而且懂得在 LED 被遮擋或眼鏡未配戴時自動停用；個人資料只會在本機儲存，不會上載也不會向 AI 服務商分享，更強調用上 ISO 27001/27701 認證、AES-256 軍規加密。
HTC VIVE Eagle AI 眼鏡目前僅限於台灣販售、售價 NT$15,600（約 HK$4,081），8 月 31 日前透過精品眼鏡店 2020EYEhaus 和電訊商台灣大哥大進行預購和體驗。
此嵌入內容無法在你所在地區提供。
更多內容：
HTC 官網
小米進軍 AI 眼鏡：12MP 相機、彩色電致變色鏡片、小愛同學
Meta 與 Oakley 聯手推出 Oakley Meta HSTN 智能眼鏡，注重運動場合應用，可錄 3K 解像度影片
緊貼最新科技資訊、網購優惠，追隨 Yahoo Tech 各大社交平台！
🎉📱 Tech Facebook：https://www.facebook.com/yahootechhk
🎉📱 Tech Instagram：https://www.instagram.com/yahootechhk/
🎉📱 Tech WhatsApp 社群：https://chat.whatsapp.com/Dg3fiiyYf3yG2mgts4Mii8
🎉📱 Tech WhatsApp 頻道：https://whatsapp.com/channel/0029Va91dmR545urVCpQwq2D
🎉📱 Tech Telegram 頻道：https://t.me/yahootechhk
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Caseware Announces Strategic Leadership Expansion to Further Accelerate Innovation, Growth and Customer Success
World-class leadership team poised to capitalize on market demand and drive next phase of growth David Marquis Toronto, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Caseware™, a global leader in AI-powered and cloud-enabled audit, financial reporting and data analytics solutions for accounting professionals, today announced its executive leadership team evolution, as the company further accelerates growth in the rapidly evolving accounting technology space. The newly appointed leadership team brings deep expertise in SaaS, artificial intelligence and accounting technology, with a strong track record of scaling enterprise software businesses and delivering customer value. 'Great companies evolve with purpose,' said David Marquis, Caseware chief executive officer. 'Caseware is positioned for its next chapter of innovation and impact. Our platform and people are aligned to our vision to power trust in the global economy.' Assembled over the course of the calendar year, this team spans critical functions - R&D, Go-to-Market, Finance and Operations - and represents decades of leadership in digital transformation, customer engagement and strategic execution. Sam High (CTO) and Andrew Smith (CPO) onboarded in Q1 2025, while Ericka Podesta McCoy (CMO) and Mike Jahoda (CCSO) onboarded in Q2 2025. Chris Nagy (CFO & COO) and Jason Rushforth (CRO) will onboard in Q3 2025. Their shared focus is on driving AI-led innovation that elevates audit quality, increases accounting workflow efficiencies, accelerates auditor effectiveness and enables exceptional client service. 'David has built a world-class team that positions Caseware to lead in AI and cloud innovation,' said Alexander Johnson, director at Hg, Caseware's majority investor. 'This leadership foundation sets the stage for sustained growth, stronger customer outcomes and continued market leadership in accounting technology.' Caseware appreciates the substantive value created by its outgoing executives for their leadership and impact during the company's transformation journey and their continued support during the transition. With this strengthened leadership foundation, Caseware is uniquely positioned to accelerate its mission of being the accounting professional's AI-powered platform of choice to drive efficiency and unlock growth. To learn more, visit our website. Attachment David Marquis CONTACT: Elise Sallis, VP, Head of Global Communications Caseware
Bloomberg
14 minutes ago
- Bloomberg
Foxconn to Operate SoftBank's Stargate AI Server Site in Ohio
Hon Hai Precision Industry Co. will operate a US factory owned by SoftBank Group Corp., setting up what's in the running to be the first manufacturing site in the Japanese company's $500 billion Stargate venture with OpenAI and Oracle Corp. SoftBank is acquiring Hon Hai's electric-vehicle plant in Ohio but the Taiwanese company will continue to run the complex after turning it into an AI server production plant, Hon Hai Chairman Young Liu said, confirming a Bloomberg News report. SoftBank will supply manufacturing gear to the factory, and a joint venture between the two companies will make AI data center-related equipment, Liu said.
Yahoo
39 minutes ago
- Yahoo
This 5p penny stock is crushing the stock market in 2025
The global stock market has been enjoying a solid run in 2025. Both the FTSE 100 and the S&P 500 have climbed by around 10% so far this year, boosted by strong corporate earnings, surging demand for artificial intelligence (AI), and a boost in aerospace and defence budgets. For many investors, it has been a productive start to the year. But one tiny penny stock is making those gains look pedestrian. Shield Therapeutics (LSE: STX), a £57.8m micro-cap pharmaceutical company, is up a staggering 108% year to date. That's more than 10 times the growth of the broader market! However, massive price jumps are not uncommon for micro-cap stocks. With a relatively small number of shareholders and limited liquidity, one small investment could make a big difference. So I decided to find out if the gains are warranted. A niche pharma stock Shield is a speciality pharmaceutical firm focused on treating iron deficiency, with its lead product, Accrufer, already on the market. At the time of writing, the shares trade at just 5.6p — a remarkable leap from a low of 2p earlier this year. Looking further back, the picture is less rosy. The share price has tumbled around 96% from its all-time high roughly five years ago. Since its inception in 2008, it has experienced several sharp rallies, including a climb from 28p to £1.84 in 2019. But now, there are signs the business could be gearing up for another chapter of growth. The company remains loss-making, but it is moving in the right direction. Its latest results showed a reduced loss of £21.3m in 2024, down from £40m the year before. Revenue surged 139% year on year, while earnings per share (EPS) improved from -4p to -2p. That's not profitability yet, but it is progress. A look under the bonnet Shield's balance sheet shows around £21m in debt against £45.9m of assets, with no free cash flow at present. A quick ratio of 0.99 suggests it can barely cover its short-term liabilities, but there isn't much wiggle room. The company has been active in shoring up its finances. It recently raised £10m in equity funding from its largest shareholder, AOP, and renegotiated a £20m debt facility on more favourable terms. It has also launched a new digital marketing campaign for Accrufer in the US, where it sees significant growth potential. Management's ambition is to become cash flow positive by the end of 2025. The verdict This is an intriguing story: a beaten-down penny stock now sprinting ahead of the broader stock market thanks to surging sales and a renewed growth strategy. The market it operates in is niche but important — iron deficiency remains a widespread and often underdiagnosed condition, especially in certain patient groups. Still, Shield is a high-risk proposition. It is concentrated on a single flagship product and its financial position leaves little margin for operational missteps. But for investors comfortable with micro-cap volatility and keen on the healthcare sector, it might just be one worth considering. If the current momentum in sales continues, I think this could be one of 2025's more memorable stock market comeback stories. The post This 5p penny stock is crushing the stock market in 2025 appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Mark Hartley has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
